Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
AbbVie Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An analysis of the operating activity ratios reveals a general decline in efficiency regarding the management of short-term assets, characterized by a lengthening of the operating cycle and a slowing of inventory turnover over the observed period.
- Inventory Management Efficiency
- A consistent downward trend is observed in inventory turnover, which decreased from a high of 5.54 in September 2022 to 3.58 by June 2026. This decline corresponds directly with a significant increase in the average inventory processing period, which rose from 74 days in March 2022 to 102 days by June 2026. The most pronounced deceleration occurred between December 2023 and June 2025, suggesting a decrease in the speed at which inventory is converted into sales.
- Receivables Collection Performance
- Receivables turnover remained relatively stable compared to inventory, though a slight overall decline is present, moving from 5.29 in March 2022 to 4.66 in June 2026. The average receivable collection period fluctuated between a minimum of 68 days (September 2022) and a maximum of 80 days (March 2024). While the collection period showed some volatility, it stabilized in the range of 73 to 78 days during the final year of the period, indicating a moderately consistent credit collection process.
- Operating Cycle Trends
- The operating cycle, representing the total time required to convert raw materials into cash through sales, has expanded significantly. The cycle began at 143 days in March 2022 and reached 180 days by June 2026. This extension is primarily driven by the lengthening of the inventory processing period rather than changes in receivable collections. The widening of the operating cycle indicates that a larger portion of capital is tied up in operating assets for longer durations, which may impact short-term liquidity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Inventory Turnover
AbbVie Inc., inventory turnover calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cost of products sold | 4,291) | 4,218) | 4,552) | 5,304) | 4,346) | 4,002) | 4,396) | 4,212) | 4,202) | 4,094) | 5,704) | 6,485) | 4,240) | 3,986) | 4,170) | 5,022) | 4,170) | 4,052) | ||||||
| Inventories | 5,127) | 5,049) | 4,951) | 4,938) | 4,960) | 4,526) | 4,181) | 4,450) | 4,218) | 4,245) | 4,099) | 3,981) | 4,055) | 3,833) | 3,579) | 3,172) | 3,396) | 3,483) | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Inventory turnover1 | 3.58 | 3.65 | 3.68 | 3.65 | 3.42 | 3.71 | 4.04 | 4.09 | 4.86 | 4.83 | 4.98 | 4.74 | 4.30 | 4.53 | 4.87 | 5.54 | 4.99 | 4.96 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | 1.87 | 1.91 | 1.93 | 1.92 | 1.88 | 1.88 | 1.84 | 1.75 | 1.42 | 1.14 | 0.89 | 1.41 | 1.38 | 1.31 | 1.30 | 1.34 | 1.40 | 1.48 | ||||||
| Bristol-Myers Squibb Co. | 5.36 | 5.20 | 5.18 | 5.31 | 5.18 | 5.28 | 5.46 | 3.57 | 3.72 | 3.70 | 4.02 | 4.33 | 4.39 | 3.93 | 4.33 | 4.77 | 4.59 | 4.55 | ||||||
| Danaher Corp. | 3.20 | 3.90 | 4.04 | 3.67 | 3.60 | 3.79 | 4.15 | 3.60 | 3.59 | 3.73 | 3.80 | 3.53 | 3.58 | 3.50 | 4.03 | 3.80 | 3.71 | 3.87 | ||||||
| Eli Lilly & Co. | 0.79 | 0.85 | 0.80 | 0.83 | 0.84 | 0.96 | 1.11 | 1.05 | 1.16 | 1.17 | 1.23 | 1.40 | 1.37 | 1.36 | 1.54 | 1.86 | 1.79 | 1.93 | ||||||
| Gilead Sciences Inc. | 3.18 | 3.21 | 3.51 | 3.47 | 3.40 | 3.55 | 3.66 | 3.62 | 3.33 | 3.59 | 3.64 | 3.49 | 3.45 | 3.57 | 3.75 | 4.71 | 4.50 | 4.50 | ||||||
| Johnson & Johnson | 2.08 | 2.13 | 2.13 | 2.08 | 2.17 | 2.24 | 2.21 | 2.15 | 2.20 | 2.32 | 2.37 | 2.46 | 2.23 | 2.36 | 2.49 | 2.68 | 2.69 | 2.77 | ||||||
| Merck & Co. Inc. | 2.90 | 2.65 | 2.46 | 2.27 | 2.25 | 2.43 | 2.49 | 2.45 | 2.39 | 2.42 | 2.54 | 2.63 | 2.66 | 2.72 | 2.95 | 3.10 | 3.06 | 2.74 | ||||||
| Pfizer Inc. | 1.72 | 1.57 | 1.51 | 1.46 | 1.52 | 1.60 | 1.65 | 1.66 | 2.05 | 2.15 | 2.45 | 2.65 | 2.31 | 3.07 | 3.82 | 3.62 | 3.66 | 3.67 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.76 | 0.74 | 0.66 | 0.64 | 0.64 | 0.63 | 0.64 | 0.64 | 0.65 | 0.66 | 0.70 | 0.72 | 0.69 | 0.67 | 0.65 | 0.83 | 0.96 | 1.27 | ||||||
| Thermo Fisher Scientific Inc. | 4.87 | 4.87 | 4.85 | 4.47 | 4.57 | 4.82 | 5.06 | 4.62 | 4.83 | 4.93 | 5.06 | 4.83 | 4.64 | 4.62 | 4.60 | 4.29 | 4.03 | 3.87 | ||||||
| Vertex Pharmaceuticals Inc. | 1.00 | 0.95 | 0.98 | 0.99 | 1.06 | 1.14 | 1.27 | 1.37 | 1.53 | 1.65 | 1.71 | 1.71 | 1.90 | 2.06 | 2.35 | 2.69 | 2.70 | 2.83 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Inventory turnover
= (Cost of products soldQ2 2026
+ Cost of products soldQ1 2026
+ Cost of products soldQ4 2025
+ Cost of products soldQ3 2025)
÷ Inventories
= (4,291 + 4,218 + 4,552 + 5,304)
÷ 5,127 = 3.58
2 Click competitor name to see calculations.
Over the analyzed period from March 2022 to June 2026, a clear divergence is observed between the growth of inventory levels and the cost of products sold, leading to a sustained decline in operational efficiency regarding inventory turnover.
- Inventory Accumulation Trends
- Inventories exhibit a consistent upward trajectory, increasing from 3,483 million US$ in March 2022 to 5,127 million US$ by June 2026. This steady growth indicates a significant increase in the volume of capital held in stock over the measured timeframe.
- Cost of Products Sold Volatility
- The cost of products sold demonstrates cyclical fluctuations rather than a linear trend. Significant peaks occurred in September 2023 (6,485 million US$) and September 2025 (5,304 million US$), yet the overall expenditure levels did not scale proportionally with the increasing inventory holdings.
- Inventory Turnover Ratio Deterioration
- The inventory turnover ratio shows a marked decrease over the period. After reaching a peak of 5.54 in September 2022, the ratio entered a persistent downward trend starting in 2024. The ratio fell from 4.83 in March 2024 to 3.58 in June 2026, with a minimum value of 3.42 recorded in June 2025.
- Operational Analysis
- The combined effect of rising inventory levels and non-proportional increases in the cost of products sold has resulted in a slower turnover of goods. This pattern indicates a reduction in inventory liquidity and an increase in the average time products remain in stock before being sold.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Receivables Turnover
AbbVie Inc., receivables turnover calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net revenues | 16,990) | 15,002) | 16,618) | 15,776) | 15,423) | 13,343) | 15,102) | 14,460) | 14,462) | 12,310) | 14,301) | 13,927) | 13,865) | 12,225) | 15,121) | 14,812) | 14,583) | 13,538) | ||||||
| Accounts receivable, net | 13,824) | 12,479) | 12,589) | 12,769) | 12,637) | 12,477) | 10,919) | 11,472) | 11,724) | 11,949) | 11,155) | 11,412) | 11,491) | 11,473) | 11,254) | 10,743) | 11,237) | 10,733) | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Receivables turnover1 | 4.66 | 5.03 | 4.86 | 4.67 | 4.62 | 4.60 | 5.16 | 4.84 | 4.69 | 4.55 | 4.87 | 4.83 | 4.88 | 4.95 | 5.16 | 5.38 | 5.10 | 5.29 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | 3.55 | 3.88 | 3.67 | 4.06 | 3.85 | 4.03 | 4.72 | 4.26 | 4.26 | 4.16 | 3.70 | 4.17 | 4.34 | 4.34 | 4.46 | 4.60 | 4.62 | 4.81 | ||||||
| Danaher Corp. | 6.33 | 6.49 | 6.28 | 6.46 | 6.74 | 6.79 | 6.75 | 6.77 | 7.15 | 7.02 | 6.09 | 6.15 | 6.64 | 6.89 | 6.40 | 7.09 | 6.81 | 6.87 | ||||||
| Eli Lilly & Co. | 3.97 | 3.92 | 3.67 | 3.69 | 3.76 | 4.07 | 4.09 | 3.97 | 3.53 | 4.56 | 3.75 | 3.93 | 3.93 | 3.68 | 4.14 | 4.35 | 4.57 | 4.64 | ||||||
| Gilead Sciences Inc. | 5.90 | 6.17 | 5.89 | 5.60 | 6.01 | 6.51 | 6.47 | 6.14 | 5.92 | 5.84 | 5.78 | 5.68 | 6.43 | 6.43 | 5.65 | 6.16 | 6.60 | 7.18 | ||||||
| Johnson & Johnson | 5.14 | 5.44 | 5.48 | 5.23 | 5.08 | 5.58 | 5.98 | 5.42 | 5.48 | 5.73 | 5.73 | 5.91 | 5.36 | 5.65 | 5.88 | 6.04 | 5.92 | 6.08 | ||||||
| Merck & Co. Inc. | 5.30 | 5.39 | 5.52 | 5.30 | 5.37 | 5.92 | 6.24 | 5.55 | 5.37 | 5.40 | 5.81 | 5.71 | 5.29 | 5.56 | 6.27 | 6.22 | 5.93 | 5.49 | ||||||
| Pfizer Inc. | 5.10 | 5.03 | 5.27 | 4.40 | 5.29 | 5.27 | 5.55 | 4.18 | 4.93 | 5.09 | 5.33 | 6.25 | 7.66 | 7.57 | 9.16 | 6.21 | 6.68 | 6.99 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.37 | 2.60 | 2.50 | 2.51 | 2.53 | 2.53 | 2.29 | 2.27 | 2.36 | 2.51 | 2.31 | 2.35 | 2.47 | 2.42 | 2.28 | 2.47 | 2.76 | 3.41 | ||||||
| Thermo Fisher Scientific Inc. | 4.90 | 4.91 | 5.01 | 4.91 | 5.03 | 5.07 | 5.23 | 5.13 | 5.33 | 5.36 | 5.21 | 5.19 | 5.43 | 5.53 | 5.53 | 5.76 | 5.53 | 5.21 | ||||||
| Vertex Pharmaceuticals Inc. | 5.90 | 6.12 | 5.85 | 6.02 | 6.03 | 6.15 | 6.85 | 6.07 | 6.24 | 5.68 | 6.31 | 6.27 | 6.11 | 5.95 | 6.19 | 6.28 | 6.26 | 6.15 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Receivables turnover
= (Net revenuesQ2 2026
+ Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025)
÷ Accounts receivable, net
= (16,990 + 15,002 + 16,618 + 15,776)
÷ 13,824 = 4.66
2 Click competitor name to see calculations.
The operational data indicates a period of revenue expansion accompanied by a moderate decline in the efficiency of accounts receivable collection. Net revenues exhibit a positive long-term trend, rising from 13,538 million USD in March 2022 to 16,990 million USD by June 2026, despite consistent quarterly fluctuations.
- Net Revenue Patterns
- A cyclical growth pattern is evident, characterized by recurring declines in the first quarter of each fiscal year followed by steady growth through the fourth quarter. This seasonality is observed consistently from 2023 through 2026, with peak revenues typically occurring in the final quarter of each year.
- Accounts Receivable Trends
- The net accounts receivable balance has increased over the analyzed period, growing from 10,733 million USD in March 2022 to 13,824 million USD by June 2026. The growth in this asset account suggests an expansion of credit extended to customers or a lengthening of the collection cycle.
- Receivables Turnover Efficiency
- The receivables turnover ratio has experienced a general downward trend, moving from a peak of 5.38 in September 2022 to 4.66 in June 2026. A period of diminished efficiency is observed between March 2023 and March 2024, where the ratio reached a low of 4.55. Although a temporary recovery to 5.16 occurred in December 2024, the ratio has largely stabilized within the 4.60 to 5.00 range throughout 2025 and 2026, indicating that receivables are being converted to cash more slowly than in the initial 2022 period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Working Capital Turnover
AbbVie Inc., working capital turnover calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current assets | 33,669) | 33,529) | 29,062) | 28,539) | 29,261) | 27,675) | 25,582) | 27,785) | 33,816) | 38,871) | 33,002) | 33,224) | 28,852) | 26,488) | 28,463) | 30,364) | 29,100) | 26,509) | ||||||
| Less: Current liabilities | 41,642) | 42,100) | 43,289) | 39,391) | 39,767) | 36,403) | 38,749) | 43,062) | 41,915) | 41,522) | 37,841) | 34,773) | 32,239) | 27,590) | 29,538) | 32,712) | 34,473) | 32,521) | ||||||
| Working capital | (7,973) | (8,571) | (14,227) | (10,852) | (10,506) | (8,728) | (13,167) | (15,277) | (8,099) | (2,651) | (4,839) | (1,549) | (3,387) | (1,102) | (1,075) | (2,348) | (5,373) | (6,012) | ||||||
| Net revenues | 16,990) | 15,002) | 16,618) | 15,776) | 15,423) | 13,343) | 15,102) | 14,460) | 14,462) | 12,310) | 14,301) | 13,927) | 13,865) | 12,225) | 15,121) | 14,812) | 14,583) | 13,538) | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Working capital turnover1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | 3.83 | 5.44 | 9.85 | 5.66 | 5.35 | 8.36 | 5.40 | 4.83 | 5.19 | 3.39 | 2.25 | 0.81 | 0.84 | 0.82 | 3.82 | 2.52 | 3.67 | 4.34 | ||||||
| Bristol-Myers Squibb Co. | 4.81 | 5.84 | 7.83 | 6.20 | 8.09 | 6.87 | 7.79 | 8.49 | 12.50 | 15.56 | 4.60 | 10.47 | 5.53 | 5.55 | 8.30 | 5.75 | 4.92 | 6.24 | ||||||
| Danaher Corp. | 4.76 | 3.83 | 4.13 | 7.39 | 5.71 | 8.27 | 8.85 | 8.73 | 8.10 | 3.60 | 4.22 | 2.18 | 3.08 | 3.81 | 4.20 | 5.00 | 5.43 | 5.91 | ||||||
| Eli Lilly & Co. | 4.71 | 3.97 | 3.19 | 2.71 | 4.92 | 4.38 | 10.32 | 6.06 | 12.62 | 5.45 | — | 31.79 | 12.21 | 5.77 | 31.84 | 14.71 | 19.45 | 8.19 | ||||||
| Gilead Sciences Inc. | 10.20 | 3.19 | 4.43 | 5.12 | 8.14 | 6.27 | 3.99 | 9.22 | 17.98 | 26.58 | 5.61 | 6.74 | 84.15 | 9.14 | 8.42 | 8.56 | 6.87 | 6.68 | ||||||
| Johnson & Johnson | 20.07 | 66.14 | 62.88 | 24.63 | 284.99 | 6.10 | 15.94 | 58.86 | 22.29 | 10.35 | 11.81 | 9.37 | 14.06 | 23.02 | — | 4.88 | 5.02 | 5.57 | ||||||
| Merck & Co. Inc. | 7.44 | 8.15 | 4.28 | 3.39 | 5.77 | 6.19 | 6.19 | 5.86 | 5.14 | 9.68 | 9.29 | 6.69 | 8.86 | 5.63 | 5.16 | 5.58 | 6.39 | 6.09 | ||||||
| Pfizer Inc. | 7.31 | 7.47 | 10.58 | 6.08 | 10.68 | 6.64 | 8.64 | 5,036.00 | — | 29.17 | — | 1.62 | 2.03 | 6.89 | 11.00 | 3.83 | 5.05 | 6.10 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.20 | 1.14 | 1.05 | 1.05 | 1.08 | 1.01 | 0.97 | 0.88 | 0.87 | 0.86 | 0.82 | 0.87 | 0.92 | 0.90 | 0.96 | 1.09 | 1.14 | 1.46 | ||||||
| Thermo Fisher Scientific Inc. | 5.59 | 5.87 | 3.30 | 5.90 | 3.64 | 4.20 | 4.87 | 4.61 | 3.96 | 4.38 | 4.05 | 4.86 | 7.40 | 10.13 | 5.46 | 5.40 | 6.03 | 6.13 | ||||||
| Vertex Pharmaceuticals Inc. | 1.46 | 1.56 | 1.64 | 1.92 | 1.82 | 1.78 | 1.83 | 1.82 | 1.92 | 1.07 | 0.93 | 0.87 | 0.90 | 0.93 | 0.85 | 0.90 | 0.93 | 0.97 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Working capital turnover
= (Net revenuesQ2 2026
+ Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025)
÷ Working capital
= (16,990 + 15,002 + 16,618 + 15,776)
÷ -7,973 = —
2 Click competitor name to see calculations.
The financial data reveals a consistent pattern of negative working capital throughout the analyzed period, contrasted by a general upward trajectory in net revenues. This combination indicates a business model that operates with current liabilities exceeding current assets, a strategy often associated with high operational efficiency or specific industry financing structures.
- Working Capital Trends
- Working capital remains negative across all twenty quarters, showing significant volatility. A notable contraction in the deficit occurred between March 2022 and December 2022, where the deficit narrowed from -6,012 million to -1,075 million. However, this trend reversed sharply beginning in 2024, reaching a peak deficit of -15,277 million by September 2024. Towards the end of the series, the deficit shows signs of moderate recovery, closing at -7,973 million by June 2026.
- Net Revenue Trajectory
- Net revenues exhibit a steady growth pattern with minor quarterly fluctuations. Revenues increased from 13,538 million in March 2022 to 16,990 million by June 2026. The growth is characterized by periodic dips, particularly in the first quarters of each year, followed by recoveries, suggesting a seasonal or cyclical nature to revenue recognition.
- Working Capital Turnover Analysis
- The working capital turnover ratio is consistently negative due to the negative working capital base. The magnitude of this ratio fluctuates inversely with the size of the working capital deficit. When the working capital deficit was at its lowest (December 2022), the turnover ratio reached its most extreme negative value, indicating high revenue generation relative to a small capital deficit. Conversely, during the period of peak deficit in late 2024, the ratio moved closer to zero, reflecting a larger reliance on short-term liabilities to support the revenue stream. The persistent negative turnover suggests that the company effectively leverages its payables and other short-term obligations to fund its operational activities and revenue growth.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Inventory Processing Period
AbbVie Inc., average inventory processing period calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Inventory turnover | 3.58 | 3.65 | 3.68 | 3.65 | 3.42 | 3.71 | 4.04 | 4.09 | 4.86 | 4.83 | 4.98 | 4.74 | 4.30 | 4.53 | 4.87 | 5.54 | 4.99 | 4.96 | ||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average inventory processing period1 | 102 | 100 | 99 | 100 | 107 | 98 | 90 | 89 | 75 | 75 | 73 | 77 | 85 | 81 | 75 | 66 | 73 | 74 | ||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | 195 | 191 | 189 | 190 | 194 | 195 | 199 | 209 | 257 | 321 | 411 | 259 | 265 | 279 | 281 | 272 | 260 | 247 | ||||||
| Bristol-Myers Squibb Co. | 68 | 70 | 70 | 69 | 70 | 69 | 67 | 102 | 98 | 99 | 91 | 84 | 83 | 93 | 84 | 76 | 79 | 80 | ||||||
| Danaher Corp. | 114 | 94 | 90 | 99 | 101 | 96 | 88 | 101 | 102 | 98 | 96 | 104 | 102 | 104 | 91 | 96 | 98 | 94 | ||||||
| Eli Lilly & Co. | 463 | 428 | 454 | 441 | 435 | 379 | 329 | 349 | 316 | 312 | 298 | 261 | 267 | 268 | 237 | 196 | 204 | 189 | ||||||
| Gilead Sciences Inc. | 115 | 114 | 104 | 105 | 108 | 103 | 100 | 101 | 110 | 102 | 100 | 105 | 106 | 102 | 97 | 78 | 81 | 81 | ||||||
| Johnson & Johnson | 176 | 172 | 171 | 176 | 168 | 163 | 165 | 169 | 166 | 158 | 154 | 149 | 164 | 155 | 147 | 136 | 136 | 132 | ||||||
| Merck & Co. Inc. | 126 | 138 | 148 | 160 | 162 | 150 | 147 | 149 | 153 | 151 | 144 | 139 | 137 | 134 | 124 | 118 | 119 | 133 | ||||||
| Pfizer Inc. | 212 | 232 | 242 | 251 | 239 | 229 | 222 | 219 | 178 | 170 | 149 | 138 | 158 | 119 | 95 | 101 | 100 | 99 | ||||||
| Regeneron Pharmaceuticals Inc. | 479 | 491 | 556 | 571 | 570 | 582 | 572 | 573 | 562 | 553 | 519 | 508 | 532 | 549 | 562 | 440 | 379 | 287 | ||||||
| Thermo Fisher Scientific Inc. | 75 | 75 | 75 | 82 | 80 | 76 | 72 | 79 | 76 | 74 | 72 | 76 | 79 | 79 | 79 | 85 | 91 | 94 | ||||||
| Vertex Pharmaceuticals Inc. | 365 | 384 | 373 | 369 | 345 | 320 | 287 | 267 | 238 | 222 | 214 | 213 | 192 | 177 | 156 | 136 | 135 | 129 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.58 = 102
2 Click competitor name to see calculations.
An analysis of the operating activity ratios reveals a progressive decline in inventory management efficiency over the period from March 2022 to June 2026. The inverse relationship between inventory turnover and the average inventory processing period indicates a systemic slowdown in the rate at which inventory is converted into sales.
- Inventory Turnover Trends
- The inventory turnover ratio exhibited relative stability during 2022, peaking at 5.54 in September 2022. However, a gradual downward trajectory began in 2023, with values fluctuating between 4.30 and 4.98. A more pronounced decline is observed starting in the latter half of 2024, where the ratio dropped from 4.86 in June to 4.04 by September. This downward trend persisted through 2025 and into 2026, ultimately reaching a period low of 3.58 by June 2026.
- Average Inventory Processing Period
- The time required to process inventory remained largely contained between 66 and 85 days throughout 2022 and 2023. A significant shift occurred in the second half of 2024, as the processing period climbed to 89 days in September and 90 days in December. This expansion accelerated in 2025, peaking at 107 days in June 2025. For the remainder of the analyzed period, including the first half of 2026, the processing period stabilized at a higher plateau, consistently remaining at or above 100 days.
- Operational Implications
- The transition from an average processing period of approximately 74 days in early 2022 to 102 days by June 2026 represents a substantial increase in the duration that capital is tied up in inventory. The simultaneous decrease in turnover suggests a potential mismatch between production or procurement levels and actual market demand, or a strategic shift toward maintaining higher safety stocks.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Receivable Collection Period
AbbVie Inc., average receivable collection period calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Receivables turnover | 4.66 | 5.03 | 4.86 | 4.67 | 4.62 | 4.60 | 5.16 | 4.84 | 4.69 | 4.55 | 4.87 | 4.83 | 4.88 | 4.95 | 5.16 | 5.38 | 5.10 | 5.29 | ||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average receivable collection period1 | 78 | 73 | 75 | 78 | 79 | 79 | 71 | 75 | 78 | 80 | 75 | 76 | 75 | 74 | 71 | 68 | 72 | 69 | ||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | 103 | 94 | 99 | 90 | 95 | 91 | 77 | 86 | 86 | 88 | 99 | 88 | 84 | 84 | 82 | 79 | 79 | 76 | ||||||
| Danaher Corp. | 58 | 56 | 58 | 56 | 54 | 54 | 54 | 54 | 51 | 52 | 60 | 59 | 55 | 53 | 57 | 51 | 54 | 53 | ||||||
| Eli Lilly & Co. | 92 | 93 | 99 | 99 | 97 | 90 | 89 | 92 | 103 | 80 | 97 | 93 | 93 | 99 | 88 | 84 | 80 | 79 | ||||||
| Gilead Sciences Inc. | 62 | 59 | 62 | 65 | 61 | 56 | 56 | 59 | 62 | 62 | 63 | 64 | 57 | 57 | 65 | 59 | 55 | 51 | ||||||
| Johnson & Johnson | 71 | 67 | 67 | 70 | 72 | 65 | 61 | 67 | 67 | 64 | 64 | 62 | 68 | 65 | 62 | 60 | 62 | 60 | ||||||
| Merck & Co. Inc. | 69 | 68 | 66 | 69 | 68 | 62 | 58 | 66 | 68 | 68 | 63 | 64 | 69 | 66 | 58 | 59 | 62 | 66 | ||||||
| Pfizer Inc. | 72 | 73 | 69 | 83 | 69 | 69 | 66 | 87 | 74 | 72 | 69 | 58 | 48 | 48 | 40 | 59 | 55 | 52 | ||||||
| Regeneron Pharmaceuticals Inc. | 154 | 140 | 146 | 146 | 144 | 144 | 160 | 161 | 155 | 146 | 158 | 156 | 148 | 151 | 160 | 148 | 132 | 107 | ||||||
| Thermo Fisher Scientific Inc. | 74 | 74 | 73 | 74 | 73 | 72 | 70 | 71 | 68 | 68 | 70 | 70 | 67 | 66 | 66 | 63 | 66 | 70 | ||||||
| Vertex Pharmaceuticals Inc. | 62 | 60 | 62 | 61 | 61 | 59 | 53 | 60 | 58 | 64 | 58 | 58 | 60 | 61 | 59 | 58 | 58 | 59 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.66 = 78
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a gradual deterioration in receivables management efficiency from early 2022 through the first quarter of 2024, followed by a period of volatility and partial stabilization through mid-2026.
- Receivables Turnover Analysis
- A general downward trend in the turnover ratio is observed during the initial period. The ratio started at a peak of 5.38 in September 2022 before declining to a low of 4.55 by March 2024. While there was a moderate recovery toward 5.16 by December 2024 and 5.03 by December 2025, the ratio remained consistently lower than the 2022 benchmarks, indicating a slower rate of converting receivables into cash.
- Average Receivable Collection Period Trends
- The collection period exhibited a corresponding increase, moving from a range of 68 to 72 days in 2022 to a peak of 80 days in March 2024. This expansion suggests a lengthening of the credit-to-cash cycle. Subsequent quarters show fluctuating performance, with the period dropping to 71 days in December 2024 before rising again to 79 days in the first half of 2025 and settling at 78 days by June 2026.
- Operational Efficiency Correlation
- A strong inverse correlation exists between the turnover ratio and the collection period. The most significant decline in turnover efficiency occurred between March 2023 and March 2024, coinciding with the highest collection duration. The inability to return the collection period to the sub-70-day levels seen in 2022 suggests a systemic shift in credit terms or a decrease in the timeliness of customer payments over the analyzed timeframe.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Cycle
AbbVie Inc., operating cycle calculation (quarterly data)
No. days
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | 102 | 100 | 99 | 100 | 107 | 98 | 90 | 89 | 75 | 75 | 73 | 77 | 85 | 81 | 75 | 66 | 73 | 74 | ||||||
| Average receivable collection period | 78 | 73 | 75 | 78 | 79 | 79 | 71 | 75 | 78 | 80 | 75 | 76 | 75 | 74 | 71 | 68 | 72 | 69 | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Operating cycle1 | 180 | 173 | 174 | 178 | 186 | 177 | 161 | 164 | 153 | 155 | 148 | 153 | 160 | 155 | 146 | 134 | 145 | 143 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | 298 | 285 | 288 | 280 | 289 | 286 | 276 | 295 | 343 | 409 | 510 | 347 | 349 | 363 | 363 | 351 | 339 | 323 | ||||||
| Danaher Corp. | 172 | 150 | 148 | 155 | 155 | 150 | 142 | 155 | 153 | 150 | 156 | 163 | 157 | 157 | 148 | 147 | 152 | 147 | ||||||
| Eli Lilly & Co. | 555 | 521 | 553 | 540 | 532 | 469 | 418 | 441 | 419 | 392 | 395 | 354 | 360 | 367 | 325 | 280 | 284 | 268 | ||||||
| Gilead Sciences Inc. | 177 | 173 | 166 | 170 | 169 | 159 | 156 | 160 | 172 | 164 | 163 | 169 | 163 | 159 | 162 | 137 | 136 | 132 | ||||||
| Johnson & Johnson | 247 | 239 | 238 | 246 | 240 | 228 | 226 | 236 | 233 | 222 | 218 | 211 | 232 | 220 | 209 | 196 | 198 | 192 | ||||||
| Merck & Co. Inc. | 195 | 206 | 214 | 229 | 230 | 212 | 205 | 215 | 221 | 219 | 207 | 203 | 206 | 200 | 182 | 177 | 181 | 199 | ||||||
| Pfizer Inc. | 284 | 305 | 311 | 334 | 308 | 298 | 288 | 306 | 252 | 242 | 218 | 196 | 206 | 167 | 135 | 160 | 155 | 151 | ||||||
| Regeneron Pharmaceuticals Inc. | 633 | 631 | 702 | 717 | 714 | 726 | 732 | 734 | 717 | 699 | 677 | 664 | 680 | 700 | 722 | 588 | 511 | 394 | ||||||
| Thermo Fisher Scientific Inc. | 149 | 149 | 148 | 156 | 153 | 148 | 142 | 150 | 144 | 142 | 142 | 146 | 146 | 145 | 145 | 148 | 157 | 164 | ||||||
| Vertex Pharmaceuticals Inc. | 427 | 444 | 435 | 430 | 406 | 379 | 340 | 327 | 296 | 286 | 272 | 271 | 252 | 238 | 215 | 194 | 193 | 188 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 102 + 78 = 180
2 Click competitor name to see calculations.
The operating cycle exhibits a clear upward trajectory over the analyzed period, indicating a general lengthening of the time required to convert current assets into cash. While the initial phase of the period showed relative stability, a marked increase in the cycle length began in late 2024 and persisted through mid-2026.
- Average Inventory Processing Period
- A significant increase in the duration of inventory holding is evident. From a low of 66 days in September 2022, the period experienced a gradual climb that accelerated sharply between June 2024 (75 days) and June 2025 (107 days). This trend indicates a reduction in inventory turnover efficiency, as the processing period ultimately stabilized at levels exceeding 100 days by the second quarter of 2026.
- Average Receivable Collection Period
- The time required to collect receivables remained comparatively stable throughout the analyzed timeframe. Values fluctuated within a narrow range between 68 and 80 days, without establishing a sustained long-term growth trend. This suggests that credit management and collection efficiency remained consistent, contributing minimally to the overall expansion of the operating cycle.
- Overall Operating Cycle
- The total operating cycle expanded from 143 days in March 2022 to 180 days by June 2026. The data reveals that this expansion was driven primarily by the increase in the inventory processing period rather than delays in receivable collections. The cycle reached a peak of 186 days in June 2025, representing a substantial increase in the time elapsed between the acquisition of inventory and the realization of cash from sales.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?